The Impact of Covid-19 Pandemic on Research and Development Process of Global Life Sciences Companies
Abstract
Objective: The objective was to better understand the level of impact of the Covid-19 pandemic on the research and development process in global life sciences companies. The study was conducted with USA, Europe, and Turkey leaders. Methods: This study was conducted with twenty functional leaders of leading global life sciences companies thru an online survey. The study was carried out between 2020 and 2021. The results were analyzed by using the Statistical 25 package. Results: Research findings showed that there had been an impact on the research and development process of the life sciences companies, mainly the productivity and effectiveness. The primary issue was the lack of university collaborations. Although several therapeutic areas were somewhat impacted, cancer was mentioned as the most affected area due to the Covid-19 pandemic. Although the respondents indicated no change was done concerning research and development strategies due to the Covid-19 pandemic, most mentioned employing some new tools, such as remote patient monitoring. Additionally, the majority mentioned that their companies developed a crisis management plan. Conclusion: The Covid-19 pandemic offered some challenges and opportunities to some life sciences companies. While the major challenge was to continue performing phase III trials, the significant opportunity was to develop vaccines and medical treatments for Covid-19ies. Keywords: Covid-19 pandemic, pharmaceutical research and development, life sciences companies,Jia, J.; Ding, J.; Liu, S.; Liao, G.; Li, J.; Duan, B.; Wang, G.; Zhang, R. Modeling the control of COVID-19: Impact of policy interventions and meteorological factors. Electronic Journal of Differential Equations, Vol. 2020, (23): 1–24 https://arxiv.org/abs/2003.02985 (accessed on 05. 09. 2022)
Li, R.; Lu, W.; Yang, X.; Feng, P.; Muqimova, O.; Chen, X.; Wei, G. Prediction of the epidemic of COVID19 based on quarantined surveillance in China. (2020) https://www.medrxiv.org/content/10.1101/2020.02.27.20027169v1.full (accessed on 05.10.2022).
Kretchy, I.; Asiedu-Dansoa, M; Kretchy, J-P. Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries, Research in Social and Administrative Pharmacy, 2021, (17): 2023–2026.
Ren, Y.F.; Rasubala, L.; Malmstrom, H.; Eliav, E. Dental Care and Oral Health under the Clouds of COVID-19. (2020). JDR clinical and translational research, 2020, (5): 202-210
Mehrotra, A.; Chernew, M.; Linetsky, D.; Hatch, H.; Cutler, D. What impact has COVID-19 had on outpatient visits? 2020: Commonwealth Fund, https:/ /www. scienceopen. Com /document? Vid= f94386d5-d706-4910-9432-8d60cc5dc3ab (accessed on 10.09.2022).
Ayati, N.; Saiyarsarai, P.; Nikfar, S. Short and long term impacts of COVID-19 on the pharmaceutical sector DARU, Journal of Pharmaceutical Sciences,2020, (28): 799-805
WHO. 2001. How to Develop and Implement a National Drug Policy.
Sarkees, M.E; Fitzgerald, M.P; Lamberton, C. The Pandemic Ripple Effect: Understanding Marketing and Public Policy Opportunities in the Pharmaceutical Industry. Journal of Public Policy & Marketing, 2020, (40): 103-104.
Peeri, N.C.; Shrestha, N.; Rahman, M.S.; Zaki, R.; Tan, Z.; Bibi, S.; Baghbanzadeh, M.;
Aghamohammadi, N.; Zhang, W.; Haque, U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International Journal of Epidemiology, 2020, (49): 717-726
Ozili, P.K.; Arun, T. (2020). Spillover of COVID-19: Impact on the global economy. (March,27, 2020) ideas. repec. Org /p /pra /mprapa /99317. (accessed on 01.12. 2022).
IQVIA Institute, Global Trends in R&D. https://iqvia-institute-global-trends-in-rd-0521forweb.pdf (accessed on 03.05.2022).
Mc Kinsey Report. COVID-19 implications for life sciences R&D: Recovery and the next normal (2020). https://www.mckinsey.com/industries/life-sciences/our-insights/Covid-19-implications-for-life-sciences-r-and-d-recovery-and-the-next-normal (accessed on 05.03.2022)
Bunts, B. Pharma’s top 20 R&D spenders in 2021, Drug Discovery & Development (2022) https://www.drugdiscoverytrends.com/pharmas-top-20-rd-spenders-in-2021 (accessed on 05.03.2022).
Schuhmacher, A; Gatto A; Kuss, Gassman, O; Hinder, M. Corona Virus Outbreak and Its Impact on the Global Pharmaceutical Industries, Drug Discovery Today 2021 (26), 10. https://pubmed.ncbi.nlm.nih.gov/33965571 (accessed on 03.10.2022).
OECD Health at a glance report. Research and development in the pharmaceutical sector (2019). https://www.oecd-ilibrary.org/sites/fc8b43f4- en / index .html? itemId =/ content / component/fc8b43f4-en (accessed on 10.05.2022).
Kayserili, A; Kiyak, M. Evaluation of R&D Activities and the Perspectives of the Participants of Pharmaceutical Companies on R&D in Turkiye. Hacettepe University Journal of the Faculty of Pharmacy, 2019, (39): 65-80
Quinn, J.B. Strategic Outsourcing Leveraging Knowledge Capabilities, Sloan Management Review, 1999, 40: 9-21
Quinn, J.B. Outsourcing Innovation: The New Engine Growth, Sloan Management Review, 2000, (41): 13-22
Festel, G., Schicker, A., Boutellier, R. Performance improvement in pharmaceutical R&D through new outsourcing models. Journal of Business Chemistry 2010, (7) 89-97
Almac Group. Industry Report: Impact of Covid -19 on the Pharma industry associated 2020. Https: // www3. almacgroup. Com /hubfs /COVID 2019 %20 Impact%20on%20Pharma%20 Outsourcing%20Survey.pdfifts in their outsourcing requirements.
| Files | ||
| Issue | Vol 9 No 2 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jppm.v9i2.13371 | |
| Keywords | ||
| Covid-19 pandemic pharmaceutical research and development life sciences companies | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
